Highdense Spółka z Ograniczoną Odpowiedzialnością (KRS 0000892967, NIP 8952229435) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. Highdense operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since April 6, 2021. Highdense's most recently reported net revenue was 7.9 K PLN for 2025.
Negative equity
Negative equity in 1 of 5 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Highdense
Identity
- Name
- Highdense Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- Limited Liability Company (LLC)
- Founded
- April 6, 2021
- Registry status as of
- July 3, 2026
- Latest entry
- July 3, 2026
- Founding act
- 02.04.2021 R.
Articles of association history (4)
- April 2, 2021: 02.04.2021 R.
- August 25, 2023: 25.08.2023 R. REP A NUMER 2709/2023 NOTARIUSZ ADAM BILIŃSKI KANCELARIA NOTARIALNA WE WROCŁAWIU UL. ŚWIĘTEGO ANTONIEGO 26 UCHYLENIE DOTYCHCZASOWEGO TEKSTU UMOWY SPÓŁKI I UCHWALENIE NOWEGO BRZMIENIA
- November 7, 2024: 07.11.2024 R. REP A NR 3009/2024 NOTARIUSZ ADAM BILIŃSKI KANCELARIA NOTARIALNA WE WROCŁAWIU UL. ŚWIĘTEGO ANTONIEGO 26 - ZMIANA PAR. 5 ORAZ PAR.6 UMOWY SPÓŁKI I NADANIE IM NOWEGO BRZMIENIA.
- April 2, 2026: 02.04.2026 R. NOTARIUSZ ADAM BILIŃSKI, KANCELARIA NOTARIALNA WE WROCŁAWIU, REP. A NR 983/2026, ZMIANA: §4, §5, §6, PRZYJĘTO TEKST JEDNOLITY UMOWY SPÓŁKI.
Activities
Other activities
Address and contact
- Address
- UL. BIERUTOWSKA, 57-59, 17, 51-317, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-13130-29524-DJUTV-20
Risk and payment profile - Highdense
Credibility rating
26.7 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
35
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/5 yrs
Board changes
3
3/5 yrs
PKD changes
1
1/5 yrs
Name changes
0
0/5 yrs
Data from 5 years of registry activity.
Credibility history
Payment reliability score from 2021–2025
Current: E (27/100)
Trend: deteriorating (-10.6 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2021–2025
Current: 169.22 PLN
Safe: 28.77 PLN
Operational status - Highdense
Founded
April 6, 2021
5 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
8.8 K PLN
Shareholders
3
shareholders
Board
1 person
Proxies: 1
Filed years
5 years
2021–2025 · profitable: 0/5
Registry entries
19
latest: July 3, 2026
Risk signals
Revenue
7.9 K PLN
2025
Net profit
-565.1 K PLN
2025
Assets
389.3 K PLN
2025
Equity
-559.3 K PLN
2025
Valuation
136.5 K PLN
Low confidence
Low confidence
Board and connected people - Highdense
People holding roles at Highdense according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Jaromir KawęckiPresident of the board
- Marcin Lech WielebskiPresident of the board, Shareholder, Commercial proxy
- Paweł Piotr ModrzyńskiBoard member, Shareholder, Commercial proxy
- Ryszard Stanisław WielebskiShareholder
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Highdense.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.